Navigation Links
IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
Date:7/9/2009

HOUSTON, July 9 /PRNewswire/ -- IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the appointment of veteran medical device executive Rick Anderson to Chairman of its Board of Directors. Thomas M. Tully, the former Chairman and CEO, has retired.

Mr. Tully spent nearly four years as CEO and established a strong, highly differentiated technology platform. Mr. Tully also led the company's effort in launching the FDA-approved SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery) IDE study. IDEV's SUPERA stent is a novel platform designed for the treatment of biliary and peripheral artery disease in the superficial femoral artery.

"Tom was instrumental in building the foundation of what is a very fast-growing and prosperous business at IDEV," said President and Chief Operating Officer Christopher M. Owens, who will oversee the day-to-day operations of IDEV. "On behalf of the entire Board and everyone at IDEV, we'd like to thank Tom for his leadership, his years of service and other numerous contributions to the Company."

Mr. Anderson is Managing Director of Austin, TX-based PTV Sciences, a healthcare venture capital and growth equity firm. Prior to PTV Sciences, Mr. Anderson served as Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation.

"We are delighted to have Rick join the company and believe his operating experience and strategic insight will be important additions to our organization," Owens said. "In particular, his expertise in the global stent business will add tremendous value as we continue to expand our product portfolio and enroll new patients in our multi-center clinical SUPERB IDE trial."

Mr. Anderson commented: "I am impressed by the potential of IDEV and its SUPERA stent, which is designed to address the unmet needs of millions of patients who suffer from biliary and peripheral vascular disease. This is a strong company with tremendous growth prospects, and I look forward to working with the management team and Board of Directors at IDEV."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDEV is based in Houston, Texas.

    Contact:  Christopher M. Owens, President and COO
              John Dame, Vice President of Finance
              IDEV Technologies Inc.
              (281) 333-1998


'/>"/>
SOURCE IDEV Technologies, Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
2. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
3. Greenway Medical Technologies To Display Live Interoperability Implementations at 2009 DIA Show
4. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
5. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
6. MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting
7. BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference
8. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
9. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
10. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
11. AIAA names top ten emerging aerospace technologies of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):